NEW YORK—RF|Binder Partners has been engaged by Competitive Technologies (CTT) to help roll out and promote its Calmare Therapy Treatment, an FDA-approved, non-invasive pain management medical device for treating high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs.
CTT is working to expand awareness of the brand and electromedical technology among medical professionals, hospitals and the general public. RF|Binder has strong experience among healthcare, pharmaceutical and technology clients.
"We chose RF|Binder because it exhibited a genuine interest and awareness in our space, and a strategic understanding of our business plan and objectives," says John Nano, CTT's chairman, president and CEO.
RF|Binder will be leading an online and traditional media relations campaign to gain exposure for the innovative Calmare Therapy Treatment.